LAVA Therapeutics Appoints Karen J. Wilson to its Board of Directors
01 April 2021 - 10:54PM
LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company
focused on applying its expertise in bispecific gamma-delta T cell
engagers (bsTCEs) to transform cancer therapy, today announced that
Karen J. Wilson has been appointed to its Board of Directors and as
chair of its Audit Committee. Ms. Wilson brings more than three
decades of finance and leadership experience in the life sciences
industry.
“I am delighted to welcome Karen to our Board of Directors,”
said Stephen Hurly, Chief Executive Officer and President. “She
joins us at an exciting time for our company as our first
gamma-delta bsTCE candidates progress towards the clinic. Her deep
experience leading finance organizations across both clinical- and
commercial-stage public life science companies will be invaluable
to LAVA as we advance our pipeline aimed at improving patient
outcomes and creating value for our shareholders.”
Ms. Wilson is a biopharmaceutical finance executive and board
member with experience in life science companies across finance,
strategy, and risk management. She currently serves on the Board of
Directors of Angion Biomedica, Connect Biopharma, and Vaxart, Inc.
She was most recently Senior Vice President of Finance at Jazz
Pharmaceuticals plc until September 2020 after serving as Vice
President of Finance and Principal Accounting Officer. Prior to
joining Jazz Pharmaceuticals in February 2011, Ms. Wilson served as
Vice President of Finance and Principal Accounting Officer at PDL
BioPharma, Inc. She also previously served as a Principal at the
consulting firm of Wilson Crisler LLC, Chief Financial Officer of
ViroLogic, Inc., Chief Financial Officer and Vice President of
Operations for Novare Surgical Systems, Inc., and as a consultant
and auditor for Deloitte & Touche LLP. Ms. Wilson is a
Certified Public Accountant and received a B.S. in Business from
the University of California, Berkeley.
“With two candidates expected to enter the clinic in 2021
following a successful IPO, I am thrilled to join LAVA’s Board,”
Ms. Wilson said. “I am very excited about the potential of the LAVA
platform to potentially transform the cancer treatment landscape. I
look forward to working with the rest of the Board and management
team to build on LAVA’s success and optimize the value of its
unique gamma-delta T cell engager platform in oncology.”
About LAVA
LAVA Therapeutics N.V. is a biotechnology company developing a
portfolio of bispecific gamma-delta T cell engagers (gamma-delta
bsTCEs) for the treatment of solid tumors and hematologic
malignancies based on its proprietary platform. The company’s
innovative approach leverages bispecific antibodies to activate
Vγ9Vδ2 T cells upon binding to membrane-expressed tumor associated
antigens. Activated Vγ9Vδ2 T cells are engaged for direct,
selective tumor cell killing. The company’s lead program, LAVA-051,
is expected to enter a Phase 1/2a clinical study in hematologic
malignancies in the first half of 2021. The company has established
a highly experienced research and development team located in
Utrecht, the Netherlands and Philadelphia, USA.
LAVA’s Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements,
including in respect of the company’s anticipated growth and
clinical developments plans, including the timing of clinical
trials. Words such as “anticipate,” “believe,” “could,” “expect,”
“should,” “plan,” “intend,” “estimate,” “potential” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to
identify forward-looking statements. These forward-looking
statements are based on LAVA’s expectations and assumptions as of
the date of this press release. Each of these forward-looking
statements involves risks and uncertainties. Actual results may
differ materially from these forward-looking statements.
Forward-looking statements contained in this press release include,
but are not limited to, statements about the progress, timing,
clinical development and scope of clinical trials and the reporting
of clinical data for LAVA’s product candidates, and the potential
use of our product candidates to treat various tumor targets. Many
factors may cause differences between current expectations and
actual results including unexpected safety or efficacy data
observed during preclinical trials, changes in expected or existing
competition, changes in the regulatory environment, the COVID-19
pandemic may disrupt our business and that of the third parties on
which we depend, including delaying or otherwise disrupting our
clinical trials and preclinical studies, manufacturing and supply
chain, or impairing employee productivity, failure of LAVA’s
collaborators to support or advance collaborations or product
candidates and unexpected litigation or other disputes, among
others. LAVA assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
Contact
Keely Zipp
k.zipp@lavatherapeutics.com
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Apr 2023 to Apr 2024